Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin

J. Elsterova, M. Palus, J. Sirmarova, J. Kopecky, HH. Niller, D. Ruzek,

. 2017 ; 8 (2) : 253-258. [pub] 20161118

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016900

Grantová podpora
NV16-34238A MZ0 CEP - Centrální evidence projektů

Tick-borne encephalitis (TBE) is a potentially lethal neuroinfection in humans, caused by TBE virus (TBEV). Currently, there are no approved therapeutic agents to treat TBE. Previously, it was suggested that application of high dose intravenous immunoglobulin (IVIG) may pose potentially successful treatment for severe cases of TBE. In this study, we determined the titers of TBEV-neutralizing antibodies in two IVIG lots originating from the same manufacturer, and tested their ability to treat a lethal TBEV-infection in a mouse model. Using an in vitro assay, more than 100-fold difference in TBEV-neutralizing capacity was demonstrated between the two individual IVIG lots. High TBEV-neutralizing activity of IVIG containing TBEV-specific antibody was confirmed in two different human neural cell lines, but IVIG without TBEV-specific antibodies had no or little effect on virus titers in the culture. In TBEV-infected mice, 90% of protection was achieved when the mice were treated with IVIG containing higher titers of TBEV-specific antibodies, whereas no immunotherapeutic effect was seen when mice were treated with IVIG without TBEV-specific antibodies. No antibody-dependent enhancement of TBEV infectivity induced by cross-reactive antibodies or by virus-specific antibodies at neutralizing or sub-neutralizing levels was observed either in cell culture or in TBEV-infected mice treated with any of the IVIG preparations. The results indicate that IVIG lots with high TBEV antibody titers might represent a post-exposure prophylaxis or first-line effective therapy of patients with a severe form of TBE.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016900
003      
CZ-PrNML
005      
20230815100803.0
007      
ta
008      
180515s2017 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ttbdis.2016.11.007 $2 doi
035    __
$a (PubMed)27884572
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Elsterova, Jana $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czechia; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czechia; Faculty of Science, University of South Bohemia, Branisovska 31, CZ-37005 Ceske Budejovice, Czechia.
245    10
$a Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin / $c J. Elsterova, M. Palus, J. Sirmarova, J. Kopecky, HH. Niller, D. Ruzek,
520    9_
$a Tick-borne encephalitis (TBE) is a potentially lethal neuroinfection in humans, caused by TBE virus (TBEV). Currently, there are no approved therapeutic agents to treat TBE. Previously, it was suggested that application of high dose intravenous immunoglobulin (IVIG) may pose potentially successful treatment for severe cases of TBE. In this study, we determined the titers of TBEV-neutralizing antibodies in two IVIG lots originating from the same manufacturer, and tested their ability to treat a lethal TBEV-infection in a mouse model. Using an in vitro assay, more than 100-fold difference in TBEV-neutralizing capacity was demonstrated between the two individual IVIG lots. High TBEV-neutralizing activity of IVIG containing TBEV-specific antibody was confirmed in two different human neural cell lines, but IVIG without TBEV-specific antibodies had no or little effect on virus titers in the culture. In TBEV-infected mice, 90% of protection was achieved when the mice were treated with IVIG containing higher titers of TBEV-specific antibodies, whereas no immunotherapeutic effect was seen when mice were treated with IVIG without TBEV-specific antibodies. No antibody-dependent enhancement of TBEV infectivity induced by cross-reactive antibodies or by virus-specific antibodies at neutralizing or sub-neutralizing levels was observed either in cell culture or in TBEV-infected mice treated with any of the IVIG preparations. The results indicate that IVIG lots with high TBEV antibody titers might represent a post-exposure prophylaxis or first-line effective therapy of patients with a severe form of TBE.
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viry klíšťové encefalitidy $x účinky léků $7 D004669
650    _2
$a klíšťová encefalitida $x terapie $7 D004675
650    _2
$a glioblastom $x virologie $7 D005909
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní imunoglobuliny $x aplikace a dávkování $7 D016756
650    _2
$a myši $7 D051379
650    _2
$a neuroblastom $x virologie $7 D009447
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Palus, Martin $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czechia; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czechia; Faculty of Science, University of South Bohemia, Branisovska 31, CZ-37005 Ceske Budejovice, Czechia.
700    1_
$a Sirmarova, Jana $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czechia.
700    1_
$a Kopecky, Jan $u Faculty of Science, University of South Bohemia, Branisovska 31, CZ-37005 Ceske Budejovice, Czechia.
700    1_
$a Niller, Hans Helmut $u Institute for Medical Microbiology and Hygiene, University of Regensburg, Franz-Josef-Strauss Allee: 11, 93053 Regensburg, Germany.
700    1_
$a Růžek, Daniel, $d 1981- $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czechia; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czechia. Electronic address: ruzekd@paru.cas.cz. $7 stk2008441707
773    0_
$w MED00167597 $t Ticks and tick-borne diseases $x 1877-9603 $g Roč. 8, č. 2 (2017), s. 253-258
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27884572 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20230815100800 $b ABA008
999    __
$a ok $b bmc $g 1300524 $s 1013740
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 8 $c 2 $d 253-258 $e 20161118 $i 1877-9603 $m Ticks and tick-borne diseases $n Ticks Tick Borne Dis $x MED00167597
GRA    __
$a NV16-34238A $p MZ0
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...